First-in-human Study to Assess the Safety and Pharmacokinetics of LML134 in Healthy Volunteers
- First Posted Date
- 2015-01-08
- Last Posted Date
- 2016-10-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 133
- Registration Number
- NCT02334449
- Locations
- 🇩🇪
Novartis Investigative Site, Berlin, Germany
Dose Range Finding Study of Bimagrumab in Sarcopenia
- First Posted Date
- 2015-01-07
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 217
- Registration Number
- NCT02333331
- Locations
- 🇨🇳
Novartis Investigative Site, Taipei, Taiwan
A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
- Conditions
- Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
- Interventions
- First Posted Date
- 2015-01-07
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 88
- Registration Number
- NCT02333370
- Locations
- 🇸🇬
Novartis Investigative Site, Singapore, Singapore
The Efficacy Study of Aclasta on Prosthetic Fixation in Postmenopausal Women After THA
- Conditions
- Prosthetic Fixation After Cementless Total Hip Arthroplasty
- Interventions
- Drug: Zoledronic acid 5mg
- First Posted Date
- 2015-01-07
- Last Posted Date
- 2019-09-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT02333344
- Locations
- 🇨🇳
Novartis Investigative Site, Shanghai, Shanghai, China
Study of Efficacy and Safety of Omalizumab in Refractory Chronic Spontaneous Urticaria Patients
- Conditions
- Chronic Spontaneous Uriticaria
- Interventions
- Other: PlaceboBiological: Omalizumab
- First Posted Date
- 2014-12-31
- Last Posted Date
- 2016-09-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 218
- Registration Number
- NCT02329223
- Locations
- 🇰🇷
Novartis Investigative Site, Seoul, Korea, Republic of
FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression
- Conditions
- Hepatocellular Carcinoma (HCC)Solid Malignancies
- Interventions
- First Posted Date
- 2014-12-25
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 172
- Registration Number
- NCT02325739
- Locations
- 🇺🇸
University of California LA Santa Monica Location, Los Angeles, California, United States
🇺🇸Uni Of TX MD Anderson Cancer Cntr, Houston, Texas, United States
🇺🇸Massachusetts General Hospital Oncology Dept, Boston, Massachusetts, United States
Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2014-12-23
- Last Posted Date
- 2022-02-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 64
- Registration Number
- NCT02323126
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center Thoractic Head/Neck Med.Onc(2), Houston, Texas, United States
🇨🇭Novartis Investigative Site, Chur, Switzerland
Long-term Follow-up of Fingolimod Phase II Study Patients
- Conditions
- Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis
- Interventions
- Other: Assessments arm
- First Posted Date
- 2014-12-04
- Last Posted Date
- 2017-03-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 177
- Registration Number
- NCT02307838
- Locations
- 🇬🇧
Novartis Investigative Site, Newcastle Upon Tyne, United Kingdom
A Randomized, Blinded, Placebo-controlled, Phase II Trial of LEE011 in Patients With Relapsed, Refractory, Incurable Teratoma With Recent Progression
- First Posted Date
- 2014-11-25
- Last Posted Date
- 2020-10-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 10
- Registration Number
- NCT02300987
- Locations
- 🇺🇸
USC Kenneth Norris Comprehensive Cancer Center Oncology Dept, Los Angeles, California, United States
🇺🇸Memorial Sloan Kettering Oncology Department., New York, New York, United States
🇪🇸Novartis Investigative Site, Madrid, Spain
Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2014-11-24
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 306
- Registration Number
- NCT02299505
- Locations
- 🇺🇸
Goshen Center for Cancer Care IU Health - SC, Indianapolis, Indiana, United States
🇺🇸Loma Linda University, Loma Linda, California, United States
🇺🇸Utah Cancer Specialists Dept.of Utah Cancer Spec. (3), Salt Lake City, Utah, United States